Improvement in the production of the human recombinant enzyme N-acetylgalactosamine-6-sulfatase (rhGALNS) in Escherichia coli using synthetic biology approaches
Abstract Previously, we demonstrated production of an active recombinant human N-acetylgalactosamine-6-sulfatase (rhGALNS) enzyme in Escherichia coli as a potential therapeutic alternative for mucopolysaccharidosis IVA. However, most of the rhGALNS produced was present as protein aggregates. Here, s...
Main Authors: | Luis H. Reyes, Carolina Cardona, Luisa Pimentel, Alexander Rodríguez-López, Carlos J. Alméciga-Díaz |
---|---|
Format: | Article |
Language: | English |
Published: |
Nature Portfolio
2017-07-01
|
Series: | Scientific Reports |
Online Access: | https://doi.org/10.1038/s41598-017-06367-w |
Similar Items
-
Hydrogel Delivery Device for the In Vitro and In Vivo Sustained Release of Active rhGALNS Enzyme
by: Michael Flanagan, et al.
Published: (2023-06-01) -
Common N-acetylgalactosamine-6-sulfate sulfatase (GALNS) exon mutations in Brazilian patients with mucopolysaccharidosis IVA (MPS IVA)
by: Tatiana Dieter, et al.
Published: (2007-01-01) -
Profound Impact of Decline in N-Acetylgalactosamine-4-Sulfatase (Arylsulfatase B) on Molecular Pathophysiology and Human Diseases
by: Joanne K. Tobacman, et al.
Published: (2022-10-01) -
Identification of galactosamine-(N-acetyl)-6-sulfatase (GALNS) as a novel therapeutic target in progression of nasopharyngeal carcinoma
by: Jin Zhang, et al.
Published: (2023-09-01) -
Identification of the iduronate-2-sulfatase proteome in wild-type mouse brain
by: Carolina Cardona, et al.
Published: (2019-05-01)